Magle Group announced that Embocept® S has received regulatory approval in Argentina. The product is intended for embolisation treatment of inoperable lung and liver tumours. Embocept® S is expected to be launched in Argentina later this quarter by Magle Group's distribution partner, BONAVIX.

EmboCept® S is a vascular embolic product based on Magle Group's proprietary polymer technology, DSM® (Degradable Starch Microsphere). It is used as a component of transarterial chemoembolisation therapy (TACE) for inoperable lung and liver tumours, where embolisation is combined with local delivery of chemotherapy. TACE is a non-surgical and minimally invasive procedure, usually performed by an interventional radiologist.

Magle Group is striving to continuously increase its revenues from existing DSM® products, both through intensified and geographically broadened direct sales activities and in alliances for marketing and distribution. In parallel, the company is pursuing the development of additional DSM® products through carefully balanced investments, with new market launches projected in the coming years.